收费全文 | 10306篇 |
免费 | 591篇 |
国内免费 | 55篇 |
耳鼻咽喉 | 86篇 |
儿科学 | 185篇 |
妇产科学 | 93篇 |
基础医学 | 1282篇 |
口腔科学 | 278篇 |
临床医学 | 675篇 |
内科学 | 2688篇 |
皮肤病学 | 270篇 |
神经病学 | 669篇 |
特种医学 | 767篇 |
外科学 | 1653篇 |
综合类 | 66篇 |
预防医学 | 310篇 |
眼科学 | 345篇 |
药学 | 647篇 |
中国医学 | 45篇 |
肿瘤学 | 893篇 |
2023年 | 49篇 |
2022年 | 37篇 |
2021年 | 167篇 |
2020年 | 115篇 |
2019年 | 147篇 |
2018年 | 204篇 |
2017年 | 189篇 |
2016年 | 215篇 |
2015年 | 254篇 |
2014年 | 285篇 |
2013年 | 364篇 |
2012年 | 520篇 |
2011年 | 559篇 |
2010年 | 347篇 |
2009年 | 288篇 |
2008年 | 472篇 |
2007年 | 548篇 |
2006年 | 506篇 |
2005年 | 579篇 |
2004年 | 498篇 |
2003年 | 528篇 |
2002年 | 506篇 |
2001年 | 352篇 |
2000年 | 335篇 |
1999年 | 282篇 |
1998年 | 111篇 |
1997年 | 95篇 |
1996年 | 73篇 |
1995年 | 77篇 |
1994年 | 74篇 |
1993年 | 59篇 |
1992年 | 200篇 |
1991年 | 172篇 |
1990年 | 153篇 |
1989年 | 168篇 |
1988年 | 140篇 |
1987年 | 157篇 |
1986年 | 148篇 |
1985年 | 147篇 |
1984年 | 107篇 |
1983年 | 76篇 |
1982年 | 47篇 |
1981年 | 38篇 |
1979年 | 70篇 |
1978年 | 43篇 |
1977年 | 39篇 |
1975年 | 44篇 |
1971年 | 38篇 |
1970年 | 37篇 |
1969年 | 40篇 |
Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status (PS) are unknown.
MethodsEnrolled patients showed disease progression after treatment with gefitinib, erlotinib, or afatinib; T790M mutation; stage IIIB, IV, or recurrent disease; and PS of 2–4. Osimertinib was orally administered at a dose of 80 mg/day. The primary endpoint of this phase II study (registration, jRCTs061180018) was response rate and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate, and safety.
ResultsThirty-three patients were enrolled, of which 69.7% and 24.2% had PS of 2 and 3, respectively. One patient was excluded due to protocol violation; in the remaining 32 patients, the response rate was 53.1%; disease control rate was 75.0%; PFS was 5.1 months; and OS was 10.0 months. The most frequent adverse event of grade 3 or higher severity was lymphopenia (12.1%). Interstitial lung disease (ILD) was observed at all grades and at grades 3–5 in 15.2% (5/33) and 6.1% (2/33) of patients, respectively. Treatment-related death due to ILD occurred in one patient. Patients negative for activating EGFR mutations after osimertinib administration had longer median PFS than those positive for these mutations.
ConclusionOsimertinib was sufficiently effective in EGFR-TKI-resistant, poor PS patients with T790M mutation-positive advanced NSCLC. Plasma EGFR mutation clearance after TKI treatment could predict the response to EGFR-TKIs.
相似文献Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8. Here, we examined the pharmacokinetic (PK) profiles of DS-8201a and DXd in cynomolgus monkeys, a cross-reactive species.
Following intravenous (iv) administration of DS-8201a, the linker was stable in plasma, and systemic DXd exposure was low. DXd was rapidly cleared following iv dosing. Biodistribution studies revealed that intact DS-8201a was present mostly in the blood without tissue-specific retention. The major pathway of excretion for DXd was the faecal route following iv administration of radiolabelled DS-8201a. The only detectable metabolite in the urine and faeces was unmetabolized DXd. DXd is a substrate of organic anion transporting polypeptides, P-gp, and breast cancer resistance protein.
In conclusion, the stable linker in circulation and the high clearance of DXd upon release resulted in the low systemic exposure to DXd. Furthermore, the minimal tissue-specific retention and rapid excretion of DXd into faeces as its unmetabolized form with potentially limited impact on drug???drug interaction as a victim were also critical elements of the PK profile of DS-8201a.